Navigation Links
Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
Date:8/30/2011

WOBURN, Mass., Aug. 30, 2011 /PRNewswire/ -- Avantra Biosciences Corporation today announced that effective immediately it is changing its name to Courtagen Life Sciences, Inc.  The company will continue to use the Avantra name for their proteomics portfolio, which includes the Avantra Biomarker System.  The Avantra Biomarker System offers users rapid, easy-to-use, quantitative multiplex protein assays using catalog or custom reagents.

Brian McKernan, CEO of Courtagen Life Sciences explained, "The name change reflects the Company's new strategic focus on developing advanced technologies in both genomic and proteomic areas and our commitment to bring additional needed technologies to the market."

In addition to the name change, the company unveiled a new logo and website, www.courtagen.com.

About Courtagen Life Sciences:

Courtagen Life Sciences, Inc. ("CLS") provides innovative and disruptive proteomic and genomic products and services to the Life Sciences industry.  Our companies deliver tools that enable researchers and clinicians to make better decisions regarding drug development and patient care.


'/>"/>
SOURCE Courtagen Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
2. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
3. Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
4. BD Biosciences Announces Winners of Research Grant Program
5. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
6. Numira Biosciences Names New Board Member
7. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
8. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
9. BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
10. Neurocrine Biosciences Reports Second Quarter 2011 Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):